In Depth 10 Mar 2021
Can Gene Therapy Cure Blindness?
Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
NightstaRx
- Latest Posts
News and Trends 4 Mar 2019
Biogen Acquires UK Biotech Developing Gene Therapy for Blindness
The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition…
News and Trends 24 Sep 2018
Gene Therapy Improves Eyesight of Patients With Inherited Blindness
UK startup Nightstar Therapeutics has reported good safety and early signs of visual improvements in a Phase I/II trial with a gene therapy for a rare form of inherited blindness.…
News and Trends 6 Mar 2018
Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial
Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing…
ADVERTISEMENT
Best in Biotech 9 Jan 2018
Happy 2018, Here Are the Top 9 European Biotech Companies To Watch
As the 2017 reports roll in, we're already turning our gaze to 2018. These are the top European biotech companies to watch in the new year. The results from last…
News and Trends 28 Sep 2017
Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs
Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing…
News and Trends 30 Jun 2017
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that…
News and Trends 11 Nov 2015
Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser
Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx ('Nightstar') biotech in Oxford an additional $35M for…
